文献速递造血干细胞移植与细胞治疗

在现代预防方案时代,儿童移植物抗宿主病发病率与供受者配型无关

Equivalent incidences of paediatric graft-versus-host disease regardless of donor-recipient matching in the era of modern prophylaxis agents.
PubMed 文献 · Br J Haematol · 2025-09-27

该回顾性单中心研究纳入0-25岁接受异基因造血干细胞移植的患者,比较单倍体、同胞全合与无关全合供者移植后急性及慢性GvHD发病率、死亡率和无GvHD无复发生存(GRFS)。结果显示三组5年累积发病率相似;含他克莫司的双药/三药方案较环孢素降低GvHD,加用阿仑单抗亦降低GvHD风险且不增加复发率。

要点

  • 单倍体、同胞全合与无关全合移植的5年任何GvHD累积发病率、全因死亡率和GRFS相似。
  • 含他克莫司的双药/三药方案较环孢素降低GvHD风险。
  • 加用阿仑单抗降低GvHD风险且不增加复发率。

核心结论

  • 在现代GvHD预防时代,儿童单倍体、同胞全合与无关全合移植受者的5年任何GvHD累积发病率、全因死亡率和GRFS相似。

研究设计与样本

  • 回顾性单中心病历抽象研究,纳入0-25岁因任何适应证接受异基因造血干细胞移植的患者。

主要发现

  • 单倍体、同胞全合与无关全合三组的5年任何GvHD累积发病率、全因死亡率和GRFS相似。
  • 含他克莫司的双药/三药方案较环孢素降低GvHD风险。
  • 加用阿仑单抗降低GvHD风险且不增加复发率。

关键数值与推荐

  • 5年任何GvHD累积发病率、全因死亡率和GRFS在单倍体、同胞全合与无关全合组间相似。
  • 含他克莫司的双药/三药方案较环孢素降低GvHD风险。
  • 加用阿仑单抗降低GvHD风险且不增加复发率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性、单中心研究。
  • 原文结论指出需开展更大规模的前瞻性研究以进一步优化儿童异基因造血干细胞移植患者的结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recipients of haploidentical and unrelated haematopoietic cell transplants (HCTs) historically had a higher risk for graft-versus-host disease (GvHD). However, with improved GvHD prophylaxis, recent data suggest adult patients undergoing transplantation from unrelated or mismatched donors now experience the rates of GvHD similar to those receiving matched related donor grafts. This finding is not yet explored in paediatric patients. The objectives of this study were to: (1) compare acute and chronic GvHD incidence, mortality and GvHD-free relapse-free survival (GRFS) among matched related donor (MRD), matched unrelated donor (MUD) and haploidentical paediatric HCT recipients in the era of enhanced GvHD prophylaxis for high-risk patients, (2) identify independent risk factors for GvHD and (3) evaluate the efficacy of various GvHD prophylactic regimens in our cohort. We conducted a retrospective, single-centre medical record abstraction among patients aged 0-25 years who underwent allogeneic HCT for any indication. The results demonstrated that 5-year cumulative incidence rates of any GvHD, all-cause mortality and GRFS are similar across the haploidentical, MRD and MUD groups. Tacrolimus-containing doublet/triplet regimens were associated with decreased GvHD, as compared to ciclosporin. Adding alemtuzumab also decreased risk for GvHD, without increasing relapse rates. Prospective studies with larger cohorts are warranted to further optimize outcomes for paediatric allogeneic HCT patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ariagno S, Greenmyer J, Kuhn A, et al. Equivalent incidences of paediatric graft-versus-host disease regardless of donor-recipient matching in the era of modern prophylaxis agents. Br J Haematol. 2025. PMID: 41014188. doi:10.1111/bjh.70184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。